Abstract
The aim of this study was to develop an SLE disease model that simulates long-term outcomes of SLE to estimate the long-term effectiveness and cost-effectiveness of SLE treatments. Longitudinal data from 1354 patients from the Hopkins Lupus Cohort were included in the analysis. Statistical models were created to estimate disease activity [Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA) SLEDAI scale] and prednisone dose over time using linear regression. Survival models for organ damage and mortality were created. The models were combined in a predictive simulation of SLE organ damage and mortality. Predictions were assessed against the Hopkins Lupus Cohort data. The analyses found that change in the annual average SLEDAI score was associated with the previous annual average SLEDAI score, renal involvement, age, male gender, African American ethnicity, anaemia, haematological involvement, increased DNA binding and low complement. The annual average prednisone dose increased for every unit increase in annual average SLEDAI. Organ damage and mortality modelling demonstrated that adjusted mean SLEDAI and binary SLEDAI organ involvement indicators predicted mortality, cardiovascular, renal, neuropsychiatric, p...Continue Reading
References
May 1, 1997·Arthritis and Rheumatism·D D GladmanG Sturfelt
Aug 16, 2000·Arthritis and Rheumatism·A Zonana-NacachM Petri
Sep 8, 2000·PharmacoEconomics·A Brennan, R Akehurst
Apr 28, 2001·Arthritis and Rheumatism·G S AlarcónJ D Reveille
Oct 23, 2001·Arthritis and Rheumatism·A HoM Petri
Oct 23, 2001·Arthritis and Rheumatism·A HoM Petri
Aug 19, 2003·Rheumatology·G S AlarcónUNKNOWN LUMINA Study Group
Dec 19, 2003·The New England Journal of Medicine·Mary J RomanJane E Salmon
Jan 14, 2004·Archives of Internal Medicine·Guillermo Ruiz-IrastorzaCiriaco Aguirre
May 27, 2004·Rheumatology·T StollD A Isenberg
Oct 12, 2004·Arthritis and Rheumatism·Sergio M A TolozaJohn D Reveille
Nov 2, 2004·Diabetologia·P M ClarkeUNKNOWN UK Prospective Diabetes Study (UKDPS) Group
May 10, 2005·Arthritis and Rheumatism·Barri J FesslerUNKNOWN LUMINA Study Group
Apr 29, 2006·Arthritis and Rheumatism·Ana M BertoliUNKNOWN LUMINA Study Group
Feb 1, 2007·Arthritis and Rheumatism·Mónica FernándezUNKNOWN LUMINA Study Group
Jul 26, 2007·Rheumatology·A M BertoliUNKNOWN LUMINA Study Group
Feb 12, 2009·The Journal of Rheumatology·Mae ThamerMichelle Petri
Aug 29, 2009·Arthritis and Rheumatism·Richard A FurieWilliam W Freimuth
Dec 30, 2009·Arthritis and Rheumatism·Joan T MerrillPaul G Brunetta
Feb 2, 2010·Lupus·J ZhangG S Alárcon
Nov 17, 2010·The Journal of Rheumatology·Sasha BernatskyUNKNOWN Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS)
Feb 8, 2011·Lancet·Sandra V NavarraUNKNOWN BLISS-52 Study Group
Sep 3, 2011·The Journal of Rheumatology·Zahi ToumaMurray B Urowitz
Sep 29, 2011·Arthritis Care & Research·M B UrowitzC Aranow
Oct 1, 2011·Arthritis Research & Therapy·Mandana NikpourDafna D Gladman
Nov 24, 2011·Rheumatology·Rekha LopezDavid A Isenberg
Mar 3, 2012·The Journal of Rheumatology·Tze Chin TanMichelle A Petri
Aug 31, 2012·Arthritis and Rheumatism·Michelle PetriLaurence S Magder
Oct 2, 2012·American Journal of Epidemiology·Laurence S Magder, Michelle Petri
Citations
Mar 19, 2016·Arthritis & Rheumatology·Ronald F van VollenhovenApril Thompson
Oct 22, 2015·PloS One·Francesca PierottiGiuseppe Turchetti
Jun 29, 2018·Lupus·H H KwonS C Bae
Jul 18, 2019·São Paulo Medical Journal = Revista Paulista De Medicina·Valentina ŽivkovićVladimir Jurišić
Nov 26, 2019·International Journal of Rheumatic Diseases·Ga Young AhnSang-Cheol Bae
Jul 30, 2020·Lupus Science & Medicine·Sean GavanKatherine Payne
May 19, 2019·Arthritis & Rheumatology·Matthias A CassiaDavid R Jayne
Jun 4, 2015·International Ophthalmology Clinics·Ian Y L YeungChi-Chao Chan
Apr 10, 2021·Lupus Science & Medicine·Deanna D HillMichelle A Petri
Jul 4, 2021·Rheumatic Diseases Clinics of North America·Christopher RedmondSarfaraz A Hasni